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OBJECTIVE—The contribution of antecedent viral infection to
the development of type 1 diabetes in humans is controversial.
Using a newer rat model of the disease, we sought to 1) identify
viruses capable of modulating diabetes penetrance, 2) identify
conditions that increase or decrease the diabetogenicity of
infection, and 3) determine whether maternal immunization
would prevent diabetes.
RESEARCH DESIGN AND METHODS—About 2% of
LEW.1WR1 rats develop spontaneous autoimmune diabetes, but
disease penetrance is much higher if weanling rats are exposed
to environmental perturbants including Kilham rat virus (KRV).
We compared KRV with other viruses for diabetogenic activity.
RESULTS—Both KRV and rat cytomegalovirus (RCMV) induced
diabetes in up to 60% of LEW.1WR1 rats, whereas H-1, vaccinia,
and Coxsackie B4 viruses did not. Simultaneous inoculation of
KRV and RCMV induced diabetes in 100% of animals. Pretreat-
ment of rats with an activator of innate immunity increased the
diabetogenicity of KRV but not RCMV and was associated with a
moderate rate of diabetes after Coxsackie B4 and vaccinia virus
infection. Inoculation of LEW.1WR1 dams with both KRV and
RCMV prior to pregnancy protected weanling progeny from
virus-induced diabetes in a virus-speciﬁc manner.
CONCLUSIONS—Exposure to viruses can affect the pen-
etrance of autoimmune diabetes in genetically susceptible ani-
mals. The diabetogenicity of infection is virus speciﬁc and is
modiﬁed by immunomodulation prior to inoculation. Maternal
immunization protects weanlings from virus-induced diabetes,
suggesting that modiﬁcation of immune responses to infection
could provide a means of preventing islet autoimmunity.
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T
ype 1 diabetes results from inﬂammatory inﬁltra-
tion of pancreatic islets (insulitis), leading to
destruction of insulin-producing -cells (1).
Much evidence suggests that the disease is
caused by nongenetic environmental factors operating in a
genetically susceptible host (2). Environmental factors
thought most likely to modulate its pathogenesis include
toxins, vaccination, diet, and infection.
An association between type 1 diabetes and viral infec-
tion was ﬁrst noted in epidemiological studies (3) and
continues to attract attention (4–6). Viruses have been
invoked to explain the increasing prevalence of diabetes
(7), seasonal variation in onset (8), and enhanced suscep-
tibility of transmigratory populations (9). Viruses associ-
ated with human diabetes include measles, congenital
rubella, mumps, and inﬂuenza B (10–13). Coxsackie B
virus RNA sequences have been found in the blood of
patients early in the disease (14), and Coxsackie antigens
can be recovered from children with recent diabetes onset
(15). Human cytomegalovirus (HCMV) major DNA-binding
protein encodes a peptide that stimulates clonal CD4

T-cells that recognize the human autoantigen GAD (16). In
addition, a molecular hybridization study of lymphocytes
using a HCMV-speciﬁc probe found evidence of viral
genome in 22% of diabetic patients but only 2.6% of control
subjects (17).
There are, however, no mechanistic data that link
human diabetes with infection, and, on the contrary, it is
plausibly argued that virus infections may prevent the
disease (4,18). The “hygiene hypothesis” posits an inverse
correlation between viral exposure and the prevalence of
both autoimmunity and allergy (19). The role of viruses in
diabetes induction has been studied in nonobese diabetic
(NOD) mice, but in this model infections are associated
with disease prevention. Coxsackie B virus accelerates
diabetes in NOD mice but only after autoimmunity has
already been initiated (20); it is also associated with
exocrine pancreatitis (21), which is not a feature of human
type 1 diabetes. Other studies have used transgenic mice
that express viral antigen on -cells (18), but these are
inherently artiﬁcial.
In rats with the high-risk major histocompatibility com-
plex (MHC) class II RT1B/Du haplotype infection with
Kilham rat parvovirus (KRV) can lead to autoimmune
diabetes (22). KRV in rats has been advocated as a model
for studying the problem of viral triggering (23). Our
objective was to investigate rat models as platforms for
evaluating the role(s) of virus infection in autoimmunity.
We report that in addition to KRV, infection with rat CMV
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which develop spontaneous disease (24). The diabetoge-
nicity of infection is shown to be dependent on age and
the preexisting state of the immune system, and innate
immune activation renders Coxsackie B4 and vaccinia
viruses diabetogenic. Finally, we demonstrate that inoc-
ulation of LEW.1WR1 dams with diabetogenic viruses
prevents induction of diabetes in weanling progeny.
Protection is both complete and virus speciﬁc.
RESEARCH DESIGN AND METHODS
Inbred LEW.1WR1 rats (RT1u/u/a) and BBDR rats (RT1u/u/u) were obtained
from BioMedical Research Models (Worcester, MA). BBDR rats develop
autoimmune diabetes after immunological perturbation but not spontaneously
(25). Animals were housed in a shower-in viral antibody–free (VAF)
facility, and periodic testing of sentinel rats documented the absence of
common rodent pathogens (listed in the online appendix Table 1 [available
at http://diabetes.diabetesjournals.org/cgi/content/full/db09–0255/DC1]). Animals
were maintained in accordance with guidelines of the institutional animal care
and use committees of the University of Massachusetts Medical School and
BioMedical Research Models and the Guide for the Care and Use of
Laboratory Animals (26). Rats were provided with autoclaved laboratory
chow (Purina 7012) and acidiﬁed water ad libitum.
Reagents. Polyinosinic:polycytidylic acid (poly I:C; Sigma, St. Louis, MO) was
dissolved in Dulbecco’s PBS, sterile ﬁltered, and stored at 20°C. The
concentration of contaminating endotoxin (LPS) was 50 units/mg (Charles
River Endosafe). Monoclonal antibody to the RCMV early antigen (mAb8) was
provided by Dr. Jan-Luuk Hillebrands (University of Groningen, The Nether-
lands). KRV (UMass strain, KRV) and Toolan’s H-1 virus (H-1) were obtained
from stocks maintained in our laboratories as described (27). RCMV was
provided by Dr. Jan-Luuk Hillebrands and maintained as described (28).
Vaccinia virus (VV) was provided by Dr. Raymond Welsh (University of
Massachusetts Medical School) (29) and Coxsackie B4 virus (CoxB4, Edwards
strain) by Dr. Charles Gauntt (University of Texas, San Antonio). CoxB4 was
maintained as described (30).
Diabetes induction. For diabetes induction studies, litters of male and
female LEW.1WR1 or BBDR rats were randomized and injected intraperito-
neally with KRV, H-1, CoxB4, VV, or RCMV at doses (in plaque forming units
[PFU]) that are indicated in the table and ﬁgure legends. Rats were either
20–25 days old (weanling), 40–45 days old, or 48–50 days old when inocu-
lated. In certain experiments, poly I:C at a dose of 1.0 g/g body wt was
injected three times on days 3, 2, and 1 relative to virus inoculation. In
one experiment, KRV and RCMV were inoculated simultaneously. In another
experiment, sequential inoculations of KRV and RCMV were performed by
injecting with one virus 4 days, 3 weeks, or 6 weeks before the other.
Detection of diabetes. Animals were screened twice weekly for glycosuria
(CliniStix; Bayer HealthCare, Elkhart, IN) beginning 1 week after the start of
each diabetes induction protocol. Diabetes in glycosuric rats was diagnosed
on the basis of a capillary glucose concentration 250 mg/dl (Accu-Chek;
Roche Diagnostics, Indianapolis, IN). Screening for diabetes was performed
until onset or day 40 after starting the induction protocol.
Histology and serology. After diagnosis of diabetes or at the end of 40 days
of observation, rats were killed and pancreata were removed and ﬁxed in 10%
buffered formalin. Parafﬁn-embedded sections of pancreas were sectioned at
4-m intervals and stained with hematoxylin and eosin. A pathologist (B.A.W.)
who was not informed of the donor’s glycemic status scored the tissues for
intensity of insulitis as follows: 0, no inﬂammatory mononuclear cell inﬁltra-
tion; 1, small numbers of mononuclear cells inﬁltrating islets with preser-
vation of islet architecture; 2, moderate numbers of inﬁltrating mononuclear
cells with preservation of islet architecture; 3, many mononuclear cells with
most islets affected and distortion of islet architecture; and 4, ﬂorid
inﬁltration and distorted islet architecture or end-stage islets with or without
residual inﬂammation.
In some experiments, RCMV antigens were visualized on 4-m formalin-
ﬁxed, parafﬁn-embedded sections of pancreas and salivary glands by reacting
with RCMV early antigen monoclonal antibody (mAb8) as described (31). In
all experiments involving RCMV, serum was obtained from diabetic animals to
conﬁrm the absence of KRV serologically (Charles River Laboratories, Wil-
mington, MA). Random samples of serum from KRV-inoculated rats uniformly
conﬁrmed the presence of anti-KRV antibodies. We were unable to test for the
presence of anti-RCMV antibodies due our inability to locate or develop a
suitable assay.
Statistics. Diabetes-free survival was analyzed using the method of Kaplan
and Meier, and the equality of nondiabetic survival distributions was tested by
log-rank statistic (32). Parametric data are given as arithmetic means  1 SD.
Latency to onset of diabetes is given as the median. Fisher’s exact statistic was
used for analyzing 2  2 tables and the 	
2 test for larger tables. Two-tailed P
values 0.05 were considered statistically signiﬁcant.
RESULTS
Both KRV and RCMV induce diabetes in weanling
LEW.1WR1 rats. KRV is known to induce diabetes in
BBDR, PVG.RT1u, and LEW.1WR1 rats, all of which ex-
press the class II B/Du MHC haplotype (22). We ﬁrst
conﬁrmed that KRV induces diabetes in LEW.1WR1 rats
inoculated at 20–25 days of age (Fig. 1 and Table 1, group
2). The percentage of diabetic animals (38%) and median
latency to onset (19 days) were similar to those observed
in BBDR rats (27). Among virus-inoculated animals, mean
insulitis scores were 3.7  0.7 (n 
 3) in diabetic rats and
0.4  0.9 in nondiabetic rats (n 
 5). We also observed that
H-1 parvovirus, which is highly homologous to KRV (33),
does not induce diabetes in LEW.1WR1 rats, all of which
were entirely free of insulitis (n 
 20) (Fig. 1 and Table 1,
group 6).
Only 10% of LEW.1WR1 rats inoculated with KRV at
40–45 days of age rats developed diabetes 19–30 days
later (n 
 20); no rats inoculated with H-1 virus at this age
became diabetic (n 
 12). Mean insulitis scores were 0.3 
0.7 among nondiabetic KRV-treated rats (n 
 18) and 0 
0 among H-1–treated rats (n 
 12). In a sample of BBDR
animals inoculated with KRV at 40–45 days of age, none
became diabetic (n 
 8).
We then found that RCMV (10
4 PFU) induced diabetes in
37% of weanling male and female LEW.1WR1 rats within
30 days of inoculation (Table 1, group 3). Median latency
to diabetes onset was 19 days, similar to that observed
after KRV inoculation (Fig. 1). Separately, none of eight
animals inoculated between 35 and 40 days of age devel-
oped diabetes or any insulitis. One of eight animals
inoculated with RCMV at 48–50 days of age developed
diabetes 8 days later, but this may have been a spontane-
ous event, as untreated LEW.1WR1 rats can become
diabetic beginning at age 46 days (24). No insulitis data are
available for this cohort.
We next tested different doses of RCMV for diabetoge-
nicity. Diabetes frequency through day 40 after inoculating
weanling LEW.1WR1 rats given 10
3,1 0
4,o r1 0
5 PFU of
virus was lower than in the previous experiment, 19% at
each dosage level (n 
 3 of 16 at each level, median
latency 15–19 days). Among rats inoculated with 10
6 PFU,
diabetes frequency was 31% (n 
 13).
Pancreata from RCMV-inoculated diabetic weanlings
uniformly showed insulitis (Fig. 2B), whereas islets from
the nondiabetic animals showed minimal inﬂammation.
Mean insulitis scores were 4.0  0.0 (n 
 7) among
diabetic rats and 0.3  0.7 (n 
 9) among nondiabetic rats.
To conﬁrm that inoculation had led to infection and to
exclude direct infection of islets as the cause of diabetes,
immunohistochemistry for the RCMV early antigen was
performed. RCMV early antigen was readily detected in
salivary gland samples (Fig. 2A) but was undetectable in
pancreata isolated from infected animals at the time of
diabetes onset (Fig. 2C).
Two other viruses were tested for diabetogenicity. In-
oculation of VV was associated with subsequent diabetes
in 1 of 14 (7%) treated rats. The diabetic animal exhibited
4 insulitis; immunohistochemistry revealed no insulin
staining with preservation of glucagon staining. The mean
insulitis score in a sample of ﬁve nondiabetic VV-inocu-
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not induce diabetes in weanling LEW.1WR1 rats (n 
 18)
(Table 1, group 4). Histology was not available for this
group.
Penetrance of diabetes is altered by concurrent in-
fection. We next asked if concurrent exposure to two
moderately diabetogenic viruses would alter the pen-
etrance of disease. Weanling LEW.1WR1 rats were in-
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FIG. 1. Frequency of diabetes in LEW.1WR1 rats. Animals 20–25 days old of either sex were randomized to groups that were untreated or
inoculated intraperitoneally with H-1 virus (10
7 PFU), KRV (10
7 PFU), or RCMV (10
4 PFU) as described in RESEARCH DESIGN AND METHODS. Rats were
observed for 40 days for onset of diabetes. Overall log-rank statistic for the dataset  13.79, df  3, P  0.003. The KRV and RCMV groups are
statistically similar (P  0.7).
TABLE 1
Frequency of induced diabetes in LEW0.1WR1 rats
Treatment type Group Poly I:C Virus n
n (%)
diabetic
Culture medium alone 1 No None 16 0 (0)
Single viral inoculations* 2 No KRV alone 8 3 (38)
3 No RCMV alone†‡ 38 14 (37)
4 No Coxsackie B4 alone§ 18 0 (0)
5 No Vaccinia alone 14 1 (7)
6 No H-1 alone 20 0 (0)
7 Yes None 18 0 (0)
Simultaneous viral inoculations¶
8 No RCMV  KRV 45 34 (76)
9 No RCMV  CoxB4 8 1 (13)
Sequential treatments**
10 Yes KRV 6 6 (100)
11 Yes RCMV 29 3 (10)
12 Yes Coxsackie B4 18 3 (17)
13 Yes Vaccinia 10 4 (40)
14 Yes H-1 6 0 (0)
Twenty- to 25-day-old male and female LEW0.1WR1 rats were inoculated intraperitoneally with the indicated viral agents with or without
pretreatment with poly I:C as described in research design and methods. Doses were as follows: KRV, 10
7 PFU; H-1, 10
7 PFU; CoxB4, 10
8 PFU;
VV, 10
6 PFU; or RCMV, 10
4 PFU. *Overall 	
2 for single virus inoculation category 
 25.48, df 
 5, P 
 0.001. †Group 3 vs. group 8, Fisher
exact statistic, P 
 0.0007. ‡Group 3 vs. group 11: Fisher exact statistic, P 
 0.02. §Group 4 vs. group 12, P 
 NS. Group 5 vs. group 13, Fisher
exact statistic, P 
 NS. ¶Group 8 vs. group 9, Fisher exact statistic, P 
 0.001. **Overall 	
2 for sequential treatments category 
 25.58, df 

3, P  0.001. In all experiments in which diabetes occurred, both male and female rats were affected. In groups 3 and 8 in which there were
larger numbers of diabetic animals, both sexes were affected in approximately equal proportions.
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diabetogenic) or with RCMV and CoxB4 virus (one diabe-
togenic, the other not). Additional cohorts were inoculated
with each of the viruses alone. In four separate trials,
animals (n 
 45) were inoculated simultaneously with
KRV and RCMV and the penetrance of diabetes ranged
from 50 to 100% (mean 76%, P  0.001 vs. RCMV alone at
the same dose [38%]) (Table 1, groups 3 and 8). In
contrast, simultaneous inoculation of RCMV and CoxB4
reduced the penetrance of diabetes (13%) (Table 1, group
9) when compared with inoculation with RCMV alone
(37%) (Table 1, group 3), but this trend did not reach
statistical signiﬁcance (P 
 0.1).
We next asked if sequential viral inoculation would
affect the frequency of diabetes. Inoculation of weanling
LEW.1WR1 rats with RCMV followed 4 days later by KRV
increased the penetrance of diabetes to 90% (n 
 10,
median latency to onset 18 days) compared with RCMV
alone (33%, P 
 0.004, median latency 18 days) (Fig. 3).
This result is consistent with the data for concurrent
inoculation of KRV and RCMV (76%) (Table 1, group 8)
and suggests that the two viruses act synergistically to
A B C
FIG. 2. RCMV antigen is detected in salivary glands but not pancreata of diabetic LEW.1WR1 rats. Salivary glands and pancreata from diabetic
LEW.1WR1 rats inoculated with RCMV were isolated within 2 days of onset of diabetes as described in RESEARCH DESIGN AND METHODS.
Representative images from salivary glands (A) and serial pancreas sections (B and C) are shown. Tissues were either stained with hematoxylin
and eosin (B) or were processed for RCMV immunohistochemistry using an antibody speciﬁc for RCMV early antigen (A and C). RCMV early
antigen could be detected in salivary glands (A, arrows) but not in pancreata (C) despite the presence of insulitis (B). 133 magniﬁcation.
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FIG. 3. Frequency of diabetes in LEW.1WR1 rats. Animals 20–25 days old of either sex were randomized to four groups. Two groups were
inoculated intraperitoneally with KRV (10
7 PFU) or RCMV (10
4 PFU) alone; two other groups were inoculated sequentially with both KRV and
RCMV at the same doses at an interval of 4 days in the order indicated in the ﬁgure. Rats were observed for 40 days for onset of diabetes. Overall
log-rank statistic for the dataset  13.55, df  3, P  0.004. The RCMV followed by KRV group was statistically signiﬁcantly different from each
of the three other groups (P < 0.012). No other pairwise comparisons were statistically signiﬁcant.
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were inoculated ﬁrst with KRV and then with RCMV, the
frequency of diabetes was 40%, comparable to that ob-
served with either virus alone (Fig. 3, n 
 10). When
LEW.1WR1 rats were inoculated sequentially with KRV
and RCMV at intervals of 3 or 6 weeks, the second
inoculation of virus was not associated with diabetes
induction in any rats not diabetic after the ﬁrst inoculation
(n 
 5–14 for each group).
To extend the outcome of the 4-day sequential inocula-
tion study in LEW.1WR1 rats, we performed a similar
study using diabetes susceptible BBDR rats. We conﬁrmed
that KRV inoculation alone induces diabetes in the BBDR
rat (Fig. 4). A single BBDR rat became diabetic 22 days
after inoculation with RCMV alone (n 
 15). In keeping
with the data from LEW.1WR1 rats (Fig. 3), inoculation of
BBDR rats with RCMV followed 4 days later by KRV
increased the penetrance of diabetes to 75% (Fig. 4, n 
 16,
median latency 18 days) compared with RCMV alone (7%,
P  0.0001). Inverting the order of infection, in contrast,
was associated with complete prevention of diabetes (Fig.
4, n 
 16. P  0.05 vs. KRV alone).
Innate immune activation selectively alters the pen-
etrance of diabetes following viral infection. Poly I:C
is an analog of double-stranded (DS) RNA that is a ligand
of both TLR3 and IFIH1 (interferon induced with helicase
C domain 1). IFIH1, also known as MDA5 (melanoma
differentiation–associated protein 5), is a retinoic acid–
inducible gene I–like helicase (RLH) (34). Pretreatment
with small doses of poly I:C enhances the diabetogenicity
of KRV in BBDR rats (33), and we hypothesized that the
outcome of the sequential infections may have been
determined by the status of the innate immune system
prior to inoculation with the second virus. We therefore
injected weanling LEW.1WR1 rats with poly I:C prior to
inoculation with virus. Injection of LEW.1WR1 rats with
poly I:C alone did not induce diabetes (n 
 18) (Table 1,
group 7) but was associated with a mild degree of insulitis
that was detectable as early as day 5 (0.6  0.8, n 
 8).
Consistent with BBDR rat data (33), pretreatment of
LEW.1WR1 rats with poly I:C prior to KRV inoculation
increased the frequency of diabetes to 100% (Table 1,
group 10). In contrast, pretreatment with poly I:C prior to
RCMV inoculation decreased the frequency of disease
from 37 to 10% (P 
 0.02) (Table 1, groups 3 and 11).
Pretreatment with poly I:C also increased the pen-
etrance of diabetes after VV inoculation from 7 to 40%
through 40 days of observation (Table 1, groups 5 and 13).
The increase in diabetes penetrance was not statistically
signiﬁcant, but 1 to 3 insulitis was present in animals
that did not become diabetic (mean score 2.2  0.8, n 
 5).
In two separate experiments, pretreatment with poly I:C
prior to CoxB4 inoculation induced diabetes in LEW.1WR1
animals at a rate of 17% (n 
 3 of 18) (Table 1, group 12).
Examination of pancreata from 12 of these animals re-
vealed 4 insulitis in 2 diabetic rats and no insulitis in any
nondiabetic animals. No exocrine pancreatitis was seen in
any of the 12 specimens. Immunohistochemistry revealed
abundant glucagon but no insulin staining in the two
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FIG. 4. Frequency of diabetes in BBDR rats. Animals 20–25 days old of either sex were randomized to four groups. Two groups were inoculated
intraperitoneally with KRV (10
7 PFU) or RCMV (10
4 PFU) alone; two other groups were inoculated sequentially with both KRV and RCMV at the
same doses at an interval of 4 days in the order indicated in the ﬁgure. Rats were observed for 40 days for onset of diabetes. Overall log-rank
statistic for the dataset  31.38, df  3, P < 0.001. The RCMV followed by KRV group was statistically signiﬁcantly different from each of the three
other groups (P < 0.01). The KRV alone group was statistically signiﬁcantly different from the KRV followed by RCMV group (P < 0.05). No other
pairwise comparisons were statistically signiﬁcant.
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nondiabetic specimens.
In a ﬁnal experiment, pretreatment with poly I:C did not
enhance the diabetogenicity of H-1 infection (n 
 6)
(Table 1, group 14), but pancreatic histology revealed that
two of six rats had 3 insulitis; the remainder were free of
inﬂammation.
Maternal immunization prevents induction of diabe-
tes. Lastly, we hypothesized that passive transfer of
antibody from dam to pup would prevent diabetes induced
by viruses. Weanling LEW.1WR1 female rats were inocu-
lated with either RCMV or both KRV and RCMV. Rats that
did not subsequently become diabetic were mated to
normal LEW.1WR1 males. Progeny of the virus-inoculated
dams were then inoculated with KRV, RCMV, or both
when weanlings. Inoculation of the progeny of naïve dams
with RCMV, KRV, or RCMV plus KRV induced diabetes at
the expected frequencies (62, 38, and 100%, respectively)
(Table 2, groups 1, 3, and 5). In contrast, pups born to
females that had been inoculated with RCMV or RCMV
plus KRV before pregnancy were protected from diabetes
induced by these speciﬁc infections (Table 2, groups 2 and
6). Pups born to RCMV-inoculated mothers, however,
were not protected from diabetes induced by KRV (Table
2, group 4).
DISCUSSION
Our data conﬁrm and extend the hypothesis that certain
viral agents have the capacity to trigger autoimmune
diabetes in genetically susceptible rodent hosts that de-
velop little (LEW.1WR1) or no (BBDR) spontaneous dis-
ease when maintained in VAF housing. Triggering of type
1 diabetes by virus alone has previously been documented
only for KRV in BBDR and LEW.1WR1 rats (22). Pretreat-
ment with poly I:C, an activator of innate immunity,
increases the penetrance of KRV-induced diabetes in both
strains, and it induces diabetes in a third strain, PVG.RT1u,
which does not become diabetic after inoculation with
KRV alone (22). Class II MHC–identical WF and PVG.R8
rats do not become diabetic in response to either KRV
alone or KRV after poly I:C (22).
We now show that diabetes reliably occurs in
LEW.1WR1 rats exposed to KRV (a single-stranded DNA
virus) and RCMV (a double-stranded DNA virus) and to a
lesser extent after exposure to VV (a double-stranded DNA
virus) and CoxB4 (a single-stranded RNA virus). The data
document that viral diabetogenicity is a complex pheno-
type with epidemiological characteristics that may help
explain why it has been difﬁcult to prove a role for
infection in human diabetes pathogenesis and identify the
relevant mechanisms.
First, for any given combination of diabetogenic virus
and susceptible inbred host genotype, disease penetrance
is incomplete; not all infected animals become diabetic
and the fraction that does varies from experiment to
experiment. For example, RCMV triggered diabetes in a
fraction of LEW.1WR1-inoculated rats in every experiment
performed, but despite the use of identical virus prepara-
tions and inbred rats in VAF housing, that fraction varied
from 20% in the dose response study to as high as 60%
in the maternal immunization study. In the case of CoxB4
virus, diabetes after inoculation was dependent on pre-
treatment with poly I:C, and even then the frequency of
disease was low (17%). At the other extreme, H-1, a
parvovirus with high homology to KRV (33) does not
trigger diabetes in BBDR or LEW.1WR1 rats with or
without poly I:C.
Second, the inﬂammatory substrate of diabetes, insuli-
tis, also exhibited variable penetrance. LEW.1WR1 rats
that became diabetic after infection with either KRV or
RCMV alone, or CoxB4 after poly I:C, exhibited intense
insulitis and selective loss of islet -cells. In contrast,
identically treated animals that did not become diabetic
were largely free of insulitis and exhibited no detectable
-cell loss. There was essentially no intermediate pheno-
type in the islets. It appears that the diabetogenic immune
response is difﬁcult to initiate with these three viruses, but
once started it goes to completion.
Third, the data document the importance of genetic
background. The frequency of spontaneous diabetes in
VAF environments is 2.5% in LEW.1WR1 rats and 0% in
BBDR or PVG.RT1u rats (22). Noninfectious immunologi-
cal perturbation of innate or adaptive immunity dramati-
cally increases the penetrance and tempo of the disease in
all three strains (22,24) but not in MHC class II–identical
LOU or WF rats (35). LEW.1WR1 rats become diabetic
after exposure to either KRV or RCMV, or after poly I:C to
VV and CoxB4. In contrast, BBDR rats develop KRV-
induced diabetes but have minimal susceptibility to
RCMV-induced disease. PVG.RT1u rats become diabetic in
response to KRV but only if pretreated with poly I:C (22).
In their aggregate, the data indicate that susceptibility to
virus-induced diabetes is dependent on speciﬁc combina-
tions of host and virus. Background genes other than the
class II MHC that may modulate the expression of type 1
diabetes after infection are under investigation. Genera-
tion of a (WF  BBDR)F2 cohort has identiﬁed a genetic
locus, Iddm20, on chromosome 17 that is speciﬁcally
associated with susceptibility to KRV-induced diabetes
(36). A different locus on chromosome 20, Iddm37, has
been identiﬁed in a (LEW.1WR1  BBDR)F2 cohort
treated with KRV (37). Fourth, susceptibility to virus-
triggered diabetes in the rat declines with age. This was
true both for older VAF animals and for older rats delib-
erately exposed 3 or 6 weeks earlier to a different virus.
This age dependence suggests that, even in a VAF envi-
ronment, developmental changes in immune response are
determinants of viral diabetogenicity. Interestingly, ge-
netic studies of spontaneous autoimmune diabetes in
lymphopenic rats have identiﬁed loci that determine age at
TABLE 2
Frequency of induced diabetes in LEW.1WR1 rats
Group
Maternal
inoculum
Progeny
inoculum nn (%) diabetic
1* None RCMV 13 8 (62)
2 RCMV RCMV 26 0 (0)
3† None KRV 8 3 (38)
4 RCMV KRV 13 8 (62)
5‡ None RCMV  KRV 10 10 (100)
6 RCMV  KRV RCMV  KRV 11 0 (0)
Twenty- to 25-day-old female LEW.1WR1 rats were either left un-
treated or were inoculated intraperitoneally with RCMV alone or
RCMV and KRV simultaneously as described in RESEARCH DESIGN AND
METHODS. Females that did not become diabetic were mated to naïve
male LEW.1WR1 rats. The resulting pups were inoculated with the
indicated viruses at 20–25 days of age and followed for 40 days or
until onset of diabetes. The doses of administered at each stage of
the experiment were 10
7 PFU for KRV and 10
4 PFU for RCMV.
*Fisher exact statistic, P  0.0001 vs. group 2. †Fisher exact statistic,
P 
 0.39 vs. group 4. ‡Fisher exact statistic, P  0.0001 vs. group 6.
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that modify the immune response over time.
Fifth, and perhaps most importantly, the data show that
viruses require a favorable immunological environment—a
“fertile ﬁeld” (40)—to be diabetogenic. Poly I:C enhances
disease induction by KRV in three rat strains (33) and, in
LEW.1WR1 rats, by CoxB4 and VV. We also show, how-
ever, that poly I:C reduces the penetrance of RCMV-
induced diabetes in the LEW.1WR1 rat. Similarly,
antecedent RCMV infection enhances the diabetogenicity
of KRV, but inverting the order of infection has little or no
effect.
While not speciﬁcally investigated in these studies, the
underlying mechanisms are likely to involve antiviral
responses evoked by the production of type 1 interferons
(IFNs) and other proinﬂammatory cytokines (34). IFNs
can promote the action of  cytotoxic effector cells and,
when expressed in -cells in insulitic islets, can elicit
-cell death (41).
Acting through different signaling pathways, both RNA
and DNA viruses induce these cytokine responses. At least
three classes of innate pattern recognition receptors are
involved: the TLRs, the RLHs (like MDA5), and nucleotide-
binding oligomerization domain–like receptors (NLRs)
(34). Viruses of different families differ greatly in their
ability to induce type 1 IFN responses via each of these
receptors, as well as in their ability to evade these re-
sponses (34). New human genome-wide association data
suggest that genetic control of these responses may be
critical for antiviral responses that protect against type 1
diabetes (42). Nejentsev et al. (42) have reported four
variants in IFIH1 that lowered type 1 diabetes risk. These
variants were predicted to alter the expression and struc-
ture of IFIH1, a cytoplasmic helicase that mediates induc-
tion of the type 1 interferon response to viral RNA and is
a target of poly I:C.
We speculate that genetically determined “tuning” of
innate immune responses to virus determines their diabe-
togenicity (43). The proinﬂammatory capability of poly I:C
clearly enhances viral diabetogenicity for agents like KRV,
but, in contrast, perhaps by impairing viral replication it
reduces the diabetogenicity of RCMV. Our sequential
infection data support this possibility. The data are con-
sistent with the suggestion that innate immune system can
act as a double-edged sword, having both a beneﬁcial role
in host defense while leading, in genetically susceptible
individuals, to upregulation of proinﬂammatory autoim-
mune responses, islet destruction, and diabetes (4,44).
Studies to quantify the type 1 IFN responses in infected
rats and to modulate diabetogenicity by manipulating
these responses are underway in our laboratories. In their
aggregate, the data suggest that the diabetogenicity of a
given virus is dependent on both the innate immune
environment in which infection occurs and on background
genes that modify the immune response.
Our observation that RCMV after KRV or poly I:C
reduced or had no effect on diabetes penetrance in the
LEW.1WR1 also suggests that, properly timed, an innate
immune response might engender the kind of protective
response implicit in the “hygiene hypothesis” (18,19).
Apropos of the hygiene hypothesis, it should be pointed
out that spontaneous diabetes does occur in the absence
of viral infection, and disease penetrance tends to increase
in an increasingly clean environment. This has been re-
ported in the BBDP (25), KDP (45), and LEW.1AR1-iddm
(46) strains. BBDP and KDP rats have mutations known to
affect T-cell number or function (25). LEW.1AR1-iddm rats
have a normal immunophenotype and the underlying
genetic mutation is not yet known (47).
Our data do provide one insight into mechanism. They
demonstrate the absence of RCMV early antigen in the
islets of diabetic LEW.1WR1 rats and suggest that -cell
infection and cytotoxicity are not the mechanism of dia-
betes induction. This observation is consistent with simi-
lar ﬁndings in BBDR rats infected with KRV (48).
Because of its relevance to human diabetes, our CoxB4
data deserve comment. Enteroviruses including CoxB4 are
among the leading candidate viral triggers of human type 1
diabetes (15,18). CoxB4 did not by itself induce the disease
in the rat strains we studied, but brief pretreatment with
poly I:C was associated with subsequent diabetes in 17% of
CoxB4-inoculated LEW.1WR1 rats. Our pretreatment pro-
tocol using three small doses of poly I:C does induce
low-grade insulitis in the LEW.1WR1 rat, and this ﬁnding
parallels the observation that CoxB3 accelerates diabetes
in NOD mice but only in the context of preexisting insulitis
(20). As is true of other viral infections in the rat, diabetes
was associated with 3 to 4 insulitis and selective destruc-
tion of insulin-producing, but not glucagon-producing,
cells, whereas islet histology in animals that did not
progress to diabetes was normal. In addition, there was no
evidence of the exocrine pancreatitis that can occur after
Coxsackie virus infection in the mouse (21). The
LEW.1WR1 rat may thus provide a platform for additional
investigation of the diabetogenicity of enteroviral infec-
tion.
Finally, we have shown that maternal exposure to a
diabetogenic virus prior to pregnancy enables dams to
produce progeny that are resistant to the diabetogenicity
of viral inoculation. Our data suggest (but do not prove)
that the passive transfer of maternal antibodies can pre-
vent viral triggering of diabetes. These data suggest that it
is the immune response to virus that is present in a
susceptible genetic context that determines the diabeto-
genicity (or protectiveness) of infection.
In conclusion, exposure to viruses, including KRV,
RCMV, VV, and CoxB4, can affect the penetrance of
autoimmune diabetes in genetically susceptible animals.
In keeping with previous analyses of both rodents and
humans (49), the connection between infections and au-
toimmunity is multifaceted and complex. We show that
low-frequency “viral footprints” (49) may be hard to de-
tect. Such low and variable rates of penetrance by viruses
of different families acting in the context of outbred
genetic backgrounds may account for the lack of ﬁrm
evidence that viruses trigger human type 1 diabetes. The
effect of infection in target tissues may also be dependent
on preinitiation of autoimmunity, as in the NOD mouse
(20), and multiple infections might act in concert to
precipitate clinical autoimmunity. As posited by the “fer-
tile ﬁeld hypothesis” (40), viral infection alone might not
be able to induce disease in the absence of other inﬂam-
matory factors. Filippi and von Herrath (18) have written
that, “based on current evidence, it…appears impossible
to assess the capacity of viruses to modulate [human] type
1 diabetes without knowledge of the state of advancement
of autoimmunity and infection history of affected individ-
uals. This is no easy task... ”W esuggest that the task may
be made more tractable by exploring rat models of virus-
induced pathogenesis in which the genetic background
can be dissected and the permissive cytokine milieu
identiﬁed and manipulated. They provide insight into the
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and prevention of diabetes in humans and may assist in the
analysis of human datasets such as those being generated
by the TEDDY study. Finally, the suggestion that immuni-
zation can prevent at least some cases of autoimmune
diabetes reanimates a longstanding prevention strategy
(50).
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